ALLR - CIK 0001860657
The table below shows Allarity Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4.49M | -$2.69M | -$1.40M | -$3.20M | -$5.75M | -$2.57M |
| Capital expenditure | $64.00K | $0.00 | - | - | - | - |
| Investing cash flow | -$64.00K | $0.00 | - | - | $809.00K | - |
| Dividends paid | - | - | - | - | - |
Allarity Therapeutics, Inc. reported operating cash flow of -$14.82M for fiscal year 2025. That is up 14.6% from -$17.35M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$7.25M (FY 2020) to -$14.82M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $262.00K | $0.00 | - | - | - | - |
| Financing cash flow | $19.74M | $11.14M | $1.38M | $1.16M | - | $2.33M |